Fig. 3From: Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapyOverall survival time regarding elevated baseline LDH (A), GGT (B), ALP (C) and CRP (D) levels at threshold > 250 U/l, > 60 U/l, > 130 U/l and > 5 mg/l, respectivelyBack to article page